KRSouth Korea
Hanmi Eppe 64 week data show weight loss holding above 10 percent in Korean Phase 3
Hanmi Pharmaceutical says patients on Eppe, Korea's first home grown GLP-1 obesity drug, lost 10.56% of body weight at 64 weeks, up from 9.75% at 40 weeks. Cross trial comparisons with Wegovy and Mounjaro remain shaky.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itHanmi says patients on Eppe, Korea's first home grown GLP-1 obesity drug, lost 10.56% of body weight on average at 64 weeks in its Korean Phase 3 trial.
Hanmi Eppe, the first GLP-1 obesity drug developed in South Korea, kept patients losing weight through 64 weeks of its local Phase 3 trial. Hanmi Pharmaceutical presented the long term results at the Obesity Society's annual meeting in the United States on 16 November, local time. Patients on the drug lost 10.56 percent of their body weight on average at 64 weeks, up from 9.75 percent at 40 weeks, the Korean business daily reported. The company did not give the placebo result for the longer period in that report.
What the 64 week data show
The trial of efpeglenatide, the active ingredient, enrolled 448 Korean adults with obesity or overweight, and was built around a body mass index range of 27 to 35, which Hanmi says reflects how obesity presents in Korea. About 30 percent of participants had a BMI below 30, about 52 percent were between 30 and 35, and around 82 percent were below 35 overall. Patients started on low amounts that were raised gradually. The gain from 40 to 64 weeks was 0.81 percentage points, according to Money Today, so average weight kept falling in the extension but much more slowly than in the first 40 weeks. Participants did not have diabetes, the report says, a detail that matters when the trial is set beside studies that enrolled people with diabetes.
Earlier reporting gave a different 40 week figure. When the Ministry of Food and Drug Safety approved the drug in October as Korea's 45th domestically developed new medicine, Korea JoongAng Daily reported an average loss of 9.02 percent at 40 weeks against 0.89 percent on placebo, with 75.1 percent of patients losing at least 5 percent of body weight. The newer 9.75 percent figure may come from a different way of analysing the same data, such as counting only patients who stayed on treatment, but neither report explains the gap. Readers comparing Hanmi Eppe with other drugs should note which analysis each number uses before drawing conclusions about how well it works.
Set against Wegovy and Mounjaro
The paper compared the result with Novo Nordisk's Wegovy. In STEP 6, a Phase 3a trial in Korea and Japan, the higher Wegovy group lost 13.2 percent of body weight at 68 weeks, against 2.1 percent on placebo. In the global STEP 1 trial, run in populations with more severe obesity, average loss at 68 weeks was 14.9 percent, with participants weighing 105.3 kilograms on average and a mean BMI of 37.9. STEP 6 also included some people with diabetes, while the Eppe trial did not. The trials differ in length, population and analysis, and none of them compared the drugs directly, a point the report itself makes.
The trials differ in length, population and analysis, and none of them compared the drugs directly, a point the report itself makes.
Hanmi's main argument is tolerability. In its Korean Phase 3 trial, 0.66 percent of patients stopped treatment for good because of serious adverse events, the company said. The paper set this against a serious adverse event rate of 9.8 percent for Wegovy in STEP 1 and rates between 5.1 and 6.9 percent across the dose groups of Lilly's Mounjaro in SURMOUNT-1. Those numbers measure different things: one counts people who quit because of serious events, the others count how often serious events occurred at all. The comparison therefore says less than it seems. A fair reading is that Eppe looked well tolerated in its own trial, not that it is safer than rivals.
Why Hanmi pitches a Korean fit
A company official said that about 82 percent of trial participants had a BMI below 35, which "differs fundamentally in its starting point" from Western studies centred on severe obesity with an average baseline BMI near 38. In that group, the official said, Eppe delivered weight loss of about 10 percent with good tolerability, so it can be called "a treatment optimized for Koreans". The pitch matches the local market, where many patients sit in lower BMI bands than in Western trials. It also serves a commercial purpose: Hanmi Eppe competes with imported brands that report larger average losses, so the company stresses fit and tolerability over the size of the headline figure.
| Measure | Hanmi Eppe Korean Phase 3 | Wegovy STEP 6 | Wegovy STEP 1 |
|---|---|---|---|
| Population | 448 Korean adults without diabetes | Adults in Korea and Japan, some with diabetes | Global, more severe obesity |
| Length | 64 weeks | 68 weeks | 68 weeks |
| Average weight loss | 10.56% at 64 weeks, 9.75% at 40 weeks | 13.2% | 14.9% |
| Placebo | 0.89% at 40 weeks in earlier report | 2.1% | Not given in report |
| Head to head with Eppe | No | No | No |
The official also said Hanmi will link treatment to diet, exercise and lifestyle support through EpiDay, its digital app for patients on the drug, and that the strategy is "not about competing on a single weight loss figure". That framing fits a crowded market. Korean patients can now choose among Wegovy, Mounjaro and Eppe, and a recent rule change has eased the carrying in of cheaper pens bought in Japan, which this site's Asia Pacific desk has followed closely. Price pressure is building, and long term data that show patients keep their results could help Hanmi argue for value even if its average weight loss trails the imported brands in cross trial comparisons.
What comes next
The next steps for Hanmi Eppe are commercial and scientific. On the commercial side, JoongAng reported at approval that Hanmi planned to supply the drug from a domestic plant and had not finalised a price, saying it wanted a level that eases the cost of long term treatment. The price and any public insurance listing will decide how far it reaches beyond private clinics. On the science side, a full publication of the 64 week results, with placebo data, the analysis method and the share of patients reaching set weight loss targets, would allow a proper reading of the extension. Hanmi has not said when or where that paper will appear.
Outside Korea, the data add to a small but growing set of GLP-1 trials run in East Asian patients, whose average BMI at entry is lower than in the large Western studies. Local data of this kind let Korean doctors judge a drug in patients who resemble their own, rather than relying only on trials run mostly elsewhere. Hanmi has not announced filings for Eppe outside Korea, and the report did not mention any. Readers can follow related decisions across the region in the story atlas. For now, the 64 week figure mainly matters to Korean doctors choosing between a local drug with modest average loss and good tolerability, and imported drugs with larger losses and more data behind them.
Conclusion
Hanmi Eppe held weight loss above 10 percent at 64 weeks in a 448 patient Korean trial, with few patients stopping for serious adverse events. The figures cannot be ranked against Wegovy or Mounjaro because the trials differ and none was head to head, and reports of the 40 week result disagree. The next markers are a full paper with placebo data, the price and any insurance listing in Korea.
Why it matters in South Korea
Eppe is the first Korean developed GLP-1 obesity drug and competes with imported Wegovy and Mounjaro. Long term data in Korean patients with lower BMI are Hanmi's main argument for a place in a market where prices are under pressure.
What to watch
A full publication of the 64 week data with placebo results, the Eppe price and any national health insurance listing, and whether Hanmi files outside Korea.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.